Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Plus500 H1 revenues up amid 'accelerating positive momentum'

(Sharecast News) - Online trading services provider Plus500 said on Monday that it has seen "accelerating positive momentum" and "material strategic progress" across the group in the six months ended 31 June. Plus500 said H1 revenues were up 4% at $415.1m, while underlying earnings rose 1% to $185.1m, and EBITDA margins contracted from 46% to 45%.

The FTSE 250-listed group said it had successfully onboarded 56,165 new customers in H12, including 29,268 in Q225, and said active customers came to 179,931, up from 175,909 in H124. Customer deposits hit a record high of $3.1bn for the six-month period.

Looking forward, Plus500 said it remains confident in the outlook for the group in FY25 and beyond.

Chief executive David Zruia said: "Plus500 delivered further operational and financial progress in H1 2025. We expanded our global presence with new regulatory licences in Canada and the UAE, added to our growing list of clearing memberships with ICE Clear US and announced the exciting acquisition of Mehta Equities in India, which will provide us access to the largest retail futures market in the world.

"This progress is underpinned by our proprietary technology, which drives our global business model and supports our relentless focus on innovation and growth, enabling the group to deliver compounded returns through the cycle."

As of 0825 BST, Plus500 shares were up 1.10% at 3,310.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.